Quick Answer
NewAmsterdam Pharma Co N.V. reported Total Revenue of $22.50 million for fiscal year 2025.
NewAmsterdam Pharma Co N.V. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $22.50M | -50.6% |
| 2024 | $45.56M | +223.4% |
| 2023 | $14.09M | -86.3% |
| 2022 | $102.69M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $348.0K | -98.8% | -98.2% |
| June 30, 2025 | $19.14M | +740.1% | +542.9% |
| March 31, 2025 | $2.98M | +112.6% | -89.8% |
| September 30, 2024 | $29.11M | +889.8% | +1177.4% |
| June 30, 2024 | $2.28M | +32.7% | +62.7% |
| March 31, 2024 | $1.40M | -83.8% | -52.4% |
| September 30, 2023 | $2.94M | — | +71.3% |
| June 30, 2023 | $1.72M | — | -80.1% |
- NewAmsterdam Pharma Co N.V. showed a decrease of -50.6% in Total Revenue compared to the prior fiscal year.
- Over the 2022–2025 period, NewAmsterdam Pharma Co N.V.’s total revenue has declined by 78.1% (from $102.69 million to $22.50 million).
- The most recent figure is from NewAmsterdam Pharma Co N.V.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: